See more : Danske Bank A/S (DNSKF) Income Statement Analysis – Financial Results
Complete financial analysis of Flotek Industries, Inc. (FTK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Flotek Industries, Inc., a leading company in the Oil & Gas Equipment & Services industry within the Energy sector.
You may be interested
- Zoomd Technologies Ltd. (ZOMD.V) Income Statement Analysis – Financial Results
- The New India Assurance Company Limited (NIACL.NS) Income Statement Analysis – Financial Results
- AD1 Holdings Limited (AD1.AX) Income Statement Analysis – Financial Results
- Vivos Therapeutics, Inc. (VVOS) Income Statement Analysis – Financial Results
- Hulic Co., Ltd. (HULCF) Income Statement Analysis – Financial Results
Flotek Industries, Inc. (FTK)
About Flotek Industries, Inc.
Flotek Industries, Inc. operates as a technology-driven chemistry and data company that serves customers across industrial, commercial, and consumer markets in the United States, the United Arab Emirates, and internationally. It operates in two segments, Chemistry Technologies (CT) and Data Analytics (DA). The CT segment designs, develops, manufactures, packages, distributes, delivers, and markets green specialty chemicals that enhance the profitability of hydrocarbon producers and cleans surfaces in commercial and personal settings to help reduce the spread of bacteria, viruses, and germs. This segment primarily serves integrated oil and gas, oilfield services, independent oil and gas, national and state-owned oil, geothermal energy, solar energy, and alternative energy companies. The DA segment designs, develops, produces, sells, and supports equipment and services that create and provide valuable information on the composition and properties of energy customers' hydrocarbon fluids. This segment's data platforms combine the energy industry's field-deployable, inline optical analyzer with proprietary cloud visualization and analytics. It sells its products directly through a mix of in-house sales professionals, as well as contractual agency agreements. The company was incorporated in 1985 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 188.06M | 136.09M | 43.27M | 53.14M | 119.35M | 177.77M | 317.10M | 262.83M | 334.36M | 449.16M | 371.07M | 312.83M | 258.79M | 146.98M | 112.55M | 226.06M | 158.01M | 100.64M | 52.87M | 21.88M | 14.84M | 13.26M | 12.56M | 1.56M | 1.79M | 3.18M |
| Cost of Revenue | 163.80M | 142.79M | 40.01M | 3.41M | 8.47M | 9.22M | 227.29M | 172.15M | 219.25M | 266.20M | 223.54M | 181.21M | 152.97M | 94.01M | 83.17M | 135.31M | 90.30M | 59.46M | 30.95M | 12.53M | 9.26M | 8.71M | 9.08M | 1.16M | 1.15M | 2.44M |
| Gross Profit | 24.26M | -6.70M | 3.26M | 49.73M | 110.89M | 168.56M | 89.81M | 90.68M | 115.11M | 182.96M | 147.53M | 131.62M | 105.82M | 52.97M | 29.38M | 90.76M | 67.71M | 41.18M | 21.92M | 9.35M | 5.58M | 4.55M | 3.48M | 396.87K | 644.37K | 742.95K |
| Gross Profit Ratio | 12.90% | -4.92% | 7.53% | 93.58% | 92.91% | 94.82% | 28.32% | 34.50% | 34.43% | 40.73% | 39.76% | 42.07% | 40.89% | 36.04% | 26.11% | 40.15% | 42.85% | 40.92% | 41.47% | 42.74% | 37.59% | 34.31% | 27.73% | 25.41% | 35.92% | 23.35% |
| Research & Development | 2.49M | 4.44M | 5.54M | 7.21M | 8.86M | 10.36M | 13.65M | 9.32M | 7.46M | 4.98M | 3.75M | 3.18M | 2.34M | 1.44M | 2.12M | 1.93M | 849.00K | 656.00K | 555.26K | 300.07K | 46.65K | 139.37K | 34.94K | 21.08K | 0.00 | 4.16K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.31M | 27.98M | 31.47M | 78.73M | 80.15M | 95.48M | 87.15M | 78.20M | 66.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 712.98K | 735.07K | 1.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 877.78K | 1.02M | 1.53M |
| SG&A | 27.87M | 27.12M | 20.17M | 16.31M | 27.98M | 31.47M | 78.73M | 80.15M | 95.48M | 87.15M | 78.20M | 66.42M | 50.61M | 41.86M | 36.94M | 46.31M | 30.64M | 18.92M | 9.49M | 5.35M | 4.79M | 7.48M | 3.77M | 1.59M | 1.75M | 2.92M |
| Other Expenses | -29.32M | 734.00K | 1.01M | 88.27M | 149.23M | -5.04M | 812.00K | -303.00K | -181.00K | -394.00K | 316.00K | -452.00K | 3.98M | 6.65M | 4.93M | 5.57M | 6.54M | 2.75M | 1.77M | 689.90K | 713.53K | 1.30M | 744.31K | 122.81K | 62.25K | 93.10K |
| Operating Expenses | 30.36M | 32.30M | 26.71M | 111.79M | 186.06M | 201.63M | 92.37M | 98.00M | 113.94M | 101.86M | 89.22M | 74.01M | 56.93M | 49.95M | 43.99M | 53.81M | 38.03M | 22.33M | 11.81M | 6.34M | 5.55M | 8.92M | 4.55M | 1.71M | 1.81M | 3.02M |
| Cost & Expenses | 164.84M | 175.09M | 66.73M | 115.20M | 194.53M | 210.85M | 319.66M | 270.15M | 333.19M | 368.06M | 312.76M | 255.22M | 209.90M | 143.96M | 127.15M | 189.12M | 128.32M | 81.79M | 42.76M | 18.87M | 14.81M | 17.63M | 13.63M | 2.88M | 2.96M | 5.46M |
| Interest Income | 0.00 | 7.05M | 78.00K | 60.00K | 2.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.22K | 43.82K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.86M | 7.05M | 78.00K | 60.00K | 2.02M | 2.87M | 2.17M | 1.98M | 1.76M | 1.61M | 2.09M | 8.10M | 15.96M | 20.22M | 15.43M | 10.23M | 3.50M | 1.01M | 827.09K | 691.57K | 618.44K | 639.92K | 415.43K | 173.78K | 173.78K | 30.45K |
| Depreciation & Amortization | 8.78M | 4.33M | 1.29M | 3.77M | 9.21M | 9.22M | 9.77M | 10.43M | 18.02M | 9.74M | 15.11M | 11.58M | 10.11M | 13.77M | 14.19M | 13.87M | 6.54M | 2.75M | 1.77M | 689.90K | 713.53K | 704.73K | 744.31K | 122.81K | 62.25K | 93.10K |
| EBITDA | 36.50M | -34.54M | -29.63M | -138.80M | -64.59M | -68.58M | 544.00K | 15.55M | 21.00M | 66.31M | 74.81M | 65.14M | 65.34M | -15.03M | -19.07M | -18.00M | 36.22M | 21.52M | 11.80M | 3.75M | 744.94K | -2.09M | -319.43K | 132.39K | -1.19M | -1.11M |
| EBITDA Ratio | 19.41% | -27.95% | -51.68% | -109.42% | -54.46% | -16.26% | 3.28% | 1.07% | 5.69% | 20.14% | 19.87% | 21.97% | 22.80% | 11.42% | -0.37% | 82.41% | 22.92% | 21.38% | 22.31% | 16.71% | 73.83% | -27.65% | -2.76% | -76.72% | -66.64% | -67.74% |
| Operating Income | 23.22M | -35.42M | -23.46M | -62.06M | -75.18M | -69.81M | -2.86M | -7.30M | -19.17M | 80.89M | 58.73M | 58.62M | 48.89M | -6.27M | -33.10M | -30.75M | 29.69M | 18.85M | 10.11M | 3.01M | -5.09M | -4.37M | -1.06M | -1.32M | -1.17M | -2.28M |
| Operating Income Ratio | 12.35% | -26.03% | -54.22% | -116.79% | -62.99% | -39.27% | -0.90% | -2.78% | -5.73% | 18.01% | 15.83% | 18.74% | 18.89% | -4.26% | -29.41% | -13.60% | 18.79% | 18.73% | 19.13% | 13.77% | -34.28% | -32.97% | -8.47% | -84.31% | -65.12% | -71.62% |
| Total Other Income/Expenses | 1.64M | -6.91M | 890.00K | 1.02M | -636.00K | -10.85M | -1.07M | 10.45M | -1.64M | 20.27M | -1.78M | -13.16M | -9.62M | -42.74M | -15.59M | -13.91M | -2.55M | -920.00K | -741.07K | -645.09K | -591.45K | -566.00 | 27.42K | 4.29K | 238.11K | -1.14M |
| Income Before Tax | 24.86M | -42.33M | -30.57M | -142.63M | -76.94M | -80.66M | -4.21M | 3.14M | -21.12M | 78.88M | 56.95M | 45.46M | 39.27M | -49.01M | -48.69M | -41.08M | 27.14M | 17.93M | 9.37M | 2.37M | 31.41K | -4.37M | -1.04M | -1.31M | -1.08M | -2.31M |
| Income Before Tax Ratio | 13.22% | -31.10% | -70.64% | -268.40% | -64.46% | -45.37% | -1.33% | 1.20% | -6.32% | 17.56% | 15.35% | 14.53% | 15.17% | -33.34% | -43.26% | -18.17% | 17.18% | 17.82% | 17.73% | 10.82% | 0.21% | -32.97% | -8.25% | -84.03% | -60.13% | -72.58% |
| Income Tax Expense | 149.00K | -22.00K | -40.00K | -6.18M | -201.00K | -7.22M | 8.84M | 1.24M | -7.65M | 25.28M | 20.77M | -4.33M | 7.86M | -5.55M | 2.02M | -9.14M | 10.41M | 6.58M | 1.65M | 213.10K | 17.01M | 451.66K | -98.65K | -8.59K | -44.24K | 184.47K |
| Net Income | 24.71M | -42.31M | -30.53M | -136.45M | -76.74M | -70.34M | -27.40M | -49.13M | -13.46M | 53.60M | 36.18M | 49.79M | 31.41M | -43.47M | -50.71M | -31.94M | 16.73M | 11.35M | 7.72M | 2.15M | -7.38M | -5.46M | -1.41M | -1.49M | -1.21M | -2.43M |
| Net Income Ratio | 13.14% | -31.09% | -70.55% | -256.77% | -64.29% | -39.57% | -8.64% | -18.69% | -4.03% | 11.93% | 9.75% | 15.92% | 12.14% | -29.57% | -45.05% | -14.13% | 10.59% | 11.28% | 14.60% | 9.84% | -49.74% | -41.20% | -11.21% | -95.16% | -67.65% | -76.46% |
| EPS | -0.12 | -3.41 | -2.50 | -11.98 | -7.84 | -7.28 | -2.85 | -5.30 | -1.47 | 4.36 | 4.23 | 6.20 | 0.60 | -1.69 | -2.59 | -1.67 | 0.91 | 0.66 | 0.53 | 0.16 | -0.62 | -0.55 | -0.22 | -0.01 | -1.50 | -4.29 |
| EPS Diluted | -0.10 | -3.41 | -2.50 | -11.98 | -7.84 | -7.28 | -2.85 | -5.26 | -1.47 | 4.26 | 4.02 | 5.80 | 0.56 | -1.69 | -2.59 | -1.67 | 0.88 | 0.61 | 0.47 | 0.16 | -0.62 | -0.55 | -0.22 | -0.01 | -1.50 | -4.29 |
| Weighted Avg Shares Out | 24.83M | 12.40M | 12.23M | 11.39M | 9.79M | 9.67M | 9.60M | 9.26M | 9.17M | 9.25M | 8.97M | 8.59M | 44.23M | 25.73M | 19.60M | 19.16M | 18.34M | 17.29M | 14.61M | 13.32M | 11.95M | 9.94M | 6.35M | 104.06M | 808.91K | 567.26K |
| Weighted Avg Shares Out (Dil) | 28.38M | 12.40M | 12.23M | 11.39M | 9.79M | 9.67M | 9.60M | 9.35M | 9.18M | 9.30M | 9.00M | 8.93M | 47.64M | 25.73M | 19.60M | 19.16M | 18.96M | 18.59M | 16.51M | 14.03M | 11.95M | 9.94M | 6.35M | 104.06M | 808.91K | 567.26K |
Colombo Port workers end strike against proposed deal with India
The trade unions had staged a protest earlier last month but suspended it following assurances from Prime Minister Mahinda Rajapaksa.
Colombo Port workers end strike against proposed deal with India
Workers at the strategic Colombo Port called off their strike on Sunday following a meeting with Prime Minister Mahinda Rajapaksa, a day after they demanded a "written pledge" from the Sri Lankan President that the country's largest port's Eastern Container...
DR MAX PEMBERTON: Kanye West and the toll of bipolar on loved ones
DR MAX PEMBERTON: Bipolar is the fourth most common mental health problem in the UK after depression, anxiety and schizophrenia, with an estimated 3 million sufferers
Sri Lankan port workers protest against proposed deal with India
"This was a diplomatic agreement with India signed by the last government – an agreement between President Sirisena and Prime Minister (Narendra) Modi," he had said. The trade unions were protesting against the alleged "Indian pressure" to prevent Sri Lanka...
Is it time to BAN electric shock therapy?
ECT is a deeply controversial treatment, and while it has been shown to help some patients with serious depression, some studies suggest the benefits may be temporary.
Dozens of patients sue the NHS over brain damage claims after therapy
Dozens of patients who underwent a highly controversial form of treatment for depression are suing the NHS claiming they suffered brain damage.
Mental Health Watchdog Renews Call for a Ban on Electroshock Device
Leading ECT researcher and advocate admits that virtually all patients experience some degree of persistent and, likely, permanent retrograde amnesia.
An Emerging Section 101 Expansion to Section 112(a) Enablement? The Federal Circuit Should Stop It Now
The most dominant, divisive issue in patent law over the last decade—Section101-eligibility and the Supreme Court’s Mayo-Alice framework—appears to have just become more divisive.
Ban 'Cuckoo's Nest' electric shock therapy, patients plead
Electro-convulsive therapy has been used to treat schizophrenia. More than 40 opponents of the treatment have written to Health Secretary Matt Hancock demanding a review of procedure.
Source: https://incomestatements.info
Category: Stock Reports